REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/02/2025
Voltar para busca
Dado oficial do USPTO
FREELINE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
04/02/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 40
Data de depósito
19/11/2018
Data de registro
04/02/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/02/2020
Última transação
04/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
GB
Examinador
REGAN, BRENDAN
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "FREELINE" in stylised text.
Titulares e representantes
Titulares
Freeline Therapeutics Limited
Representantes
Samantha M. Quimby Frost Brown Todd LLC
Classificação técnica
Classes Nice
Classe 5Classe 40
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalmedical and veterinary preparations for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for use in treatmentamelioration or prophylaxis of genetic or inherited or non-infectious diseases or disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorders or cancers; pharmaceuticalmedical and clinical preparations for treatmentamelioration or prophylaxis of chronic or systemic diseasenamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorders or cancers; pharmaceuticalmedical and clinical preparations for use in gene therapy for preventionamelioration or treatment of disordersnamely of blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases; pharmaceuticalmedical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for preventionamelioration or treatment of disordersnamely blood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersautoimmune disordershepatological disorderscentral or peripheral nervous system disordersocular or ophthalmological disordersmuscular disordersmusculoskeletal disordersbone disorderscardiovascular or vascular disordersendocrine disordersgastrointestinal disordersneurological disordersdermatological disordersrespiratory disordersurological disorderscancers or infectious diseases
Classe 40
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/02/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/08/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/06/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/05/2020
FIMP
FINAL DISPOSITION PROCESSED
18/05/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
04/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/11/2019
PUBO
PUBLISHED FOR OPPOSITION
19/11/2019
GPNX
NOTIFICATION PROCESSED BY IB
15/11/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/10/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
30/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/10/2019
ALIE
ASSIGNED TO LIE
17/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2019
RFNT
REFUSAL PROCESSED BY IB
06/04/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/03/2019
RFRR
REFUSAL PROCESSED BY MPU
21/03/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/03/2019
CNRT
NON-FINAL ACTION WRITTEN
11/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
08/03/2019
DOCK
ASSIGNED TO EXAMINER
04/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/03/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
01/03/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/02/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FREELINE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.